SCHEMBL5464433

SCHEMBL5464433

COc1cccc(OC)c1/C=C1\C(=O)Nc2ccccc21

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 3/20 0.78
CSNK1A1 P48729 2/20 0.78
CSNK1E P49674 2/20 0.78
SMN1; SMN2 Q16637 2/20 0.78
L3MBTL1 Q9Y468 1/20 0.78
GMNN O75496 1/20 0.78
ALDH1A1 P00352 1/20 0.78
LMNA P02545 1/20 0.78
TP53 P04637 1/20 0.78
CYP1A2 P05177 1/20 0.78
CYP3A4 P08684 1/20 0.78
MAPT P10636 1/20 0.78
CYP2C9 P11712 1/20 0.78
HPGD P15428 1/20 0.78
MAPK1 P28482 1/20 0.78
CYP2C19 P33261 1/20 0.78
THPO P40225 1/20 0.78
RAB9A P51151 1/20 0.78
BLM P54132 1/20 0.78
PMP22 Q01453 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5464438 1.00 CSNK1D (0.78) CSNK1DCSNK1A1CSNK1ESMN1; SMN2L3MBTL1
SCHEMBL15016038 0.87 CSNK1D (0.68) CSNK1DCSNK1A1CSNK1ESMN1; SMN2L3MBTL1
Ic261 SCHEMBL905701 0.87 CSNK1D (1.00) CSNK1DCSNK1A1CSNK1ESMN1; SMN2L3MBTL1
Ic261 SCHEMBL29467414 0.87 CSNK1D (1.00) CSNK1DCSNK1A1CSNK1ESMN1; SMN2L3MBTL1
Ic261 SCHEMBL3697594 0.87 CSNK1D (1.00) CSNK1DCSNK1A1CSNK1ESMN1; SMN2L3MBTL1
Ic261 SCHEMBL2786157 0.87 CSNK1D (1.00) CSNK1DCSNK1A1CSNK1ESMN1; SMN2L3MBTL1
SCHEMBL29367529 0.85 NPC1 (1.00) CSNK1DCSNK1A1CSNK1ESMN1; SMN2L3MBTL1
SCHEMBL5469692 0.85 NPC1 (1.00) CSNK1DCSNK1A1CSNK1ESMN1; SMN2L3MBTL1
SCHEMBL16442345 0.85 NPC1 (1.00) CSNK1DCSNK1A1CSNK1ESMN1; SMN2L3MBTL1
SCHEMBL5469690 0.85 NPC1 (1.00) CSNK1DCSNK1A1CSNK1ESMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US claimed
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167488-A1 Novel therapeutic use MAG, PMP22, MYT1 CSNK1D 3982/4885CSNK1A1 3608/4885CSNK1E 2824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.